The role of denosumab for prevention of skeletal-related complications in multiple myeloma;El Papel de Denosumab para la Prevención de Complicaciones Músculo-Esqueletales Debido a Mieloma Múltiple

Annals of Pharmacotherapy

Volumn 47, Issue 7-8, 2013, Pages 1069-1074

  Hageman, Kelly ^a   Patel, Kiki Chandni ^a   Mace, Kimberly ^a,b   Cooper, Maryann R ^a  

^a Massachusetts College of Pharmacy and Health Sciences   (United Kingdom)

^b Exeter Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CREATININE; DENOSUMAB; PLACEBO; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ADVANCED CANCER; ANEMIA; ARTICLE; BONE ATROPHY; BONE DISEASE; BONE LESION; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CONSTIPATION; CREATININE URINE LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HYPOCALCEMIA; INFECTION; INFECTIONS ASSOCIATED WITH OTHER INFECTIONS OR CONDITIONS; JAW OSTEONECROSIS; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; NAUSEA; NEPHROTOXICITY; OPEN STUDY; OSTEOCLAST; OSTEOCLAST ACTIVITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN URINE LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKELETAL RELATED EVENT; SOLID TUMOR; TREATMENT DURATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE MYELOMA; OSTEOLYSIS; RANK LIGAND;

EID: 84880051666     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R776     Document Type: Article

References (19)

1. Terpos E, Efstathiou E, Christoulas D, Roussou M, Katodritou E, Dimopoulos MA. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. Expert Opin Biol Ther 2009;9:465-79. doi: 10.1517/14712590902845610
2. Longo V, Brunetti O, D'Oronzo S, Dammacco F, Silvestris F. Therapeutic approaches to myeloma bone disease: an evolving story. Cancer Treat Rev 2012;38:787-97. doi: 10.1016/j.ctrv.2012.03.004
3. Kennedy K, Patel H. Update on the pharmacological prevention of skeletal-related events in cancer patients. Orthopedics 2011;34:982-5. doi: 10.3928/01477447-20111021-21
4. Product Information. Zometa (zoledronic acid). East Hanover, NJ: Novartis, November 2012.
5. Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. May Clinic Proc 2005;80:1371-82. doi: 10.4065/80.10.1371
6. Goldschmidt H, Lannert H, Bommer J, Ho AD. Multiple myeloma and renal failure. Nephrol Dial Transplant 2000;15:301-4. doi: 10.1093/ndt/15.3.301
7. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990;150:863-9. doi: 10.1001/archinte.1990.00390160111022
8. Product information. Aredia (pamidronate disodium). East Hanover, NJ: Novartis, May 2012.
9. Castellano D, Sepulveda JM, Garcia-Escobar I, Rodriguez-Antolin A, Sundlov A, Cortes-Funes H. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist 2011;16:136-45. doi: 10.1634/theoncologist.2010-0154
10. Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48:3082-92. doi: 10.1016/j.ejca.2012.08.002
11. Product information. Xgeva (denosumab). Thousand Oaks, CA: Amgen, February 2013.
12. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27:1564-71. doi: 10.1200/JCO.2008.19.2146
13. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-35. doi: 10.1200/JCO.2005.06.091
14. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32. doi: 10.1200/JCO.2010.31.3304
15. Vadhan-Raj S, von Moos R, Fallowfield LJ, et al. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol 2012;23:3045-51. doi: 10.1093/annonc/mds175
16. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-72. doi: 10.1200/JCO.2007.12.1269
17. Palumbo A, Durie BG, Raje N, et al. Denosumab compared with zoledronic acid for preventing skeletal complications in patients with multiple myeloma: a randomized, phase 3 double-blind, double-dummy trial. Ann Oncol (ESMO abstracts) 2012;23(suppl 9):ix360.
18. Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc., updated periodically (accessed 2013 Jun 6).
19. Barlev A, Song X, Ivanov B, Setty V, Chung K. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010;16:693-702.